Related Experiment Video
Updated: Apr 18, 2026
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
Evaluating the efficacy of probiotic on treatment in patients with small intestinal bacterial overgrowth (SIBO)--a
A R Khalighi1, M R Khalighi, R Behdani
1Department of Internal Medicine, Quaem Hospital, Mashhad University of Medical Science (MUMS), Mashhad, Iran.
Background & Objectives:
Small intestinal bacterial overgrowth (SIBO) leads to several gastrointestinal (GI) problems and complications leading to malabsorption. The effectiveness of probiotics in the treatment of SIBO syndrome has not been well studied. This pilot study was aimed to assess the efficacy of a probiotic consisting of lactobacilli in the treatment of SIBO.
Methods:
In this study, 30 cases suffering from chronic abdominal pain or diarrhoea and with a positive hydrogen breath test were randomized in a double-blind manner into two groups: probiotic drug user and control group. After an initial 3-week aggressive therapy with broad-spectrum antibiotics, a 15-day maintenance antibiotic therapy with lactol was administered for the study group and the same regimen without lactol for the control group. After six months the HBT result and the GI symptoms were analyzed and compared between the two groups.
Results:
The result of hydrogen breath test and the clinical symptoms in patients receiving the maintenance regimen with lactol probiotic showed a better response. The hydrogen breath test turned negative in 93.3 per cent of those receiving lactol compared to 66.7 per cent of the controls. In all the cases receiving lactol, the abdominal pain disappeared completely ( p =0.002). In addition, other GI problems including flatulence, belching and diarrhoea significantly improved in the study group ( p < 0.05).
Interpretation & Conclusions:
Based on the preliminary data it seems that adding lactol probiotic to the maintenance therapy of small intestinal bacterial overgrowth patients on routine antibiotic therapy will be beneficial in preventing the complications of this syndrome.
Insights
This pilot study found that adding lactol probiotic to antibiotic therapy significantly improved symptoms and test results for small intestinal bacterial overgrowth (SIBO). The probiotic group showed better outcomes in treating SIBO complications.
Area of Science:
- Gastroenterology
- Microbiology
- Clinical Medicine
Background:
- Small intestinal bacterial overgrowth (SIBO) causes various gastrointestinal issues and malabsorption.
- The therapeutic role of probiotics in SIBO management remains under-investigated.
- This study addresses the need for evidence on probiotic efficacy in SIBO treatment.
Purpose of the Study:
- To evaluate the effectiveness of a lactobacilli-based probiotic in treating SIBO.
- To assess the impact of probiotics on gastrointestinal symptoms and hydrogen breath test (HBT) results in SIBO patients.
Main Methods:
- A double-blind, randomized pilot study involving 30 patients with chronic GI symptoms and positive HBT.
- Participants received either broad-spectrum antibiotics followed by a 15-day maintenance therapy with lactol probiotic or a placebo regimen.
- Outcomes, including HBT results and GI symptoms, were assessed after six months.
Main Results:
- The lactol probiotic group demonstrated a significantly higher rate of negative HBT results (93.3%) compared to the control group (66.7%).
- Complete resolution of abdominal pain was observed in all patients receiving lactol (p=0.002).
- Significant improvements in other GI symptoms like flatulence, belching, and diarrhea were noted in the probiotic group (p<0.05).
Conclusions:
- Adding lactol probiotic to maintenance antibiotic therapy appears beneficial for SIBO patients.
- Probiotic supplementation may help prevent complications associated with SIBO.
- This pilot data suggests a promising role for probiotics in SIBO management.
More Related Videos
06:07Evaluating Cell Death Using Cell-Free Supernatant of Probiotics in Three-Dimensional Spheroid Cultures of Colorectal Cancer Cells
Published on: June 13, 2020
05:41Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
Related Concept Videos
01:22Probiotics
01:21Drugs for Treatment of Constipation-Predominant IBS
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are: